Increasing midazolam sedation levels associated with decreased energy expenditure in mechanically ventilated patients
This prospective self-controlled cohort study evaluated 74 critically ill patients with clear consciousness who required mechanical ventilation. The study examined the impact of different midazolam sedation levels, categorized as mild (RASS 0 to 1), moderate (RASS -2 to -3), and severe (RASS -4 to -5), on metabolic outcomes.
Results indicated that oxygen consumption, carbon dioxide production, and resting energy expenditure (REE) gradually decreased as sedation increased (p < 0.05). Specific REE values reported were 1,347 ± 129 kcal/d for mild sedation, 1,236 ± 137 kcal/d for moderate sedation, and 1,140 ± 108 kcal/d for severe sedation, with all levels showing significant variation (p < 0.05). Multiple logistic regression analysis identified sedation, sex, age, and body mass index (BMI) as independent factors influencing REE.
Safety and tolerability data, including adverse events or discontinuation rates, were not reported. The study period spanned from September 2023 to September 2024. While the findings suggest that sedation depth affects energy expenditure in this population, clinicians should consider these results alongside other independent metabolic drivers such as age and BMI when managing nutritional support.